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Background: Cavotricuspid isthmus (CTI) ablation is the treatment of choice in preventing recurrences of typical
atrial flutter (AFl). However, little is known about long-term quality of life (QoL) after CTI ablation.
Methods and results: From 01/2003 to 05/2005, 94 patients who consecutively underwent typical AFl ablation
were included in the study. An SF-36 health questionnaire was self-administered before ablation and at follow-up.
Transformed scores were calculated, adjusted for age and sex and then normalized and standardized for the Spanish
population. Additionally, the minimal important differences (MID) were calculated to assess the smallest change in QoL
that patients perceived as positive. A linear regression model was constructed to assess long-term QoL predictors. All
SF-36 scales were lower than Spanish population scores. After a mean (SD) follow-up of 6.25 (0.5) years, all scales, except
Bodily Pain, were higher than baseline. There was a significant difference for Physical Role (46.4 vs. 38.6, p < 0.001),
Vitality (44.4 vs. 41.9, p = 0.038) and Mental Health (46.1 vs. 42.0, p = 0.001). However, only Physical Role achieved the
criteria for MID. Recurrence of AFl, basal QoL, history of diabetes mellitus, atrial fibrillation and oral anticoagulation were
predictors of long-term QoL.
Conclusion: CTI ablation provides a significant improvement in long-term QoL for the dimensions of Physical Role,
Vitality and Mental Health, although the smallest positive change that patients perceive as positive was only observed
for Physical Role. Previous diabetes mellitus, atrial fibrillation, oral anticoagulation, basal QoL and AFl recurrence were
determinants of a worse long-term QoL.
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Typical atrial flutter (AFl) is characterized by a macro-
reentry circuit around the tricuspid annulus; this circuit
contains a propagating wave and an excitable gap. The
anterior barrier of the activation wave is formed by the
tricuspid annulus, while the posterior barrier is formed
by the crista terminalis, the eustaquian ridge and its
prolongation, the eustaquian valve [1]. The cavotricus-
pid isthmus (CTI) is a critical component of the circuit; its
ablation is the technique available to block the circuit
[1-3]. The success rate of this technique is currently high* Correspondence: pilicgrandio@yahoo.es
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article, unless otherwise stated.(90 to 100%) and complications are extremely rare. For
these reasons, CTI ablation is a first-line treatment [4].
However, there is little information available about the
quality of life (QoL) in patients who have undergone typ-
ical AFL ablation. There are only a few studies published
about QoL; furthermore, in those studies, QoL is assessed
using different questionnaires, with short- to medium-
term follow-up periods [5]. Our objective was to assess
long-term QoL (more than five years) and to evaluate the
differences between basal and long-term QoL in patients
who had undergone a typical AFl ablation procedure. We
did this using the SF-36 questionnaire, which is widely
used and validated, and also a new tool for determining
the minimal important differences (MID). We also evalu-
ated factors related to long-term QoL.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Study population
A total of 94 patients admitted consecutively to our insti-
tution for typical AFl ablation between January 2003 and
May 2005 were included in the study.
The inclusion criteria were: a) aged over 18 years, b) the
presence of one or more episodes of documented AFl in
the previous six months, and c) a demonstration by elec-
trophysiological study of either CTI-dependent AFl or
CTI permeability, accompanied by an electrocardiogram
taken during a clinical episode consistent with typical AFl
in those cases in which the procedure was performed in
sinus rhythm.
The exclusion criteria were: a) atypical AFl (non CTI-
dependent), b) patients with an implantable cardiac defibril-
lator (ICD), c) patients who had undergone cardiac surgery
or invasive cardiac procedures (coronary angioplasty or car-
diac stimulation devices) in the previous month, and d)
those patients with a life expectancy of less than one year
or patients who were unable to complete the questionnaire.
Assessment of QoL with the SF-36
All 94 patients included in the study self-administered
the SF-36 during the 24–48 hours pre-ablation proced-
ure and at follow-up. The mean (SD) follow-up was 6.26
(0.5) years and was completed for 96.8% of patients.
We use the Spanish version 2.0 of the SF-36 and modi-
fied the standard form to include a longer follow-up period.
After all questionnaires had been administered, the 36
items were grouped and coded according to the SF-36
Health Survey manual and its interpretation guide [6,7].
A linear transformation of all scores was performed
on a scale from 0 to 100, with 0 representing the worst
health status on that scale or dimension, and 100 the
best health status.
All dimensions were then standardized and normalized
for the Spanish population, adjusted for age and sex, such
that the reference values have a mean (SD) of 50 (10). This
allowed the results to be compared directly with the refer-
ence population, and for scores above or below 50 to indi-
cate better or worse health, respectively, than the average
for the Spanish general population. The Physical and
Mental Summary Components (PCS and MCS) were also
calculated, each of which was also normalized to an over-
all population mean (SD) of 50 (10).
In addition, to quantify the magnitude of the change
in health status, the effect size (ES) and the standardized
response mean (SRM) were calculated for each dimen-
sion [8,9]. The ES is calculated as the difference between
means (before and after an intervention) divided by the
SD, prior to the intervention. The SRM is calculated as
the difference in the mean values of each dimension be-
tween the baseline and follow-up, divided by the SD of
the difference between the baseline and the follow-up.Thus, any improvement in positive values reflects the
number of times that the result contains the SD of the
basal group (ES) or the SD of the difference between the
groups (SRM).
The ES and SRM translate the changes into a standard
unit of measurement that allows the different measures
to be compared: a) <0.20: very small amount of change,
b) from 0.20 to 0.5: small amount of change, c) from 0.6
to 0.80: moderate magnitude of change, d) > 0.80: large
amount of change.
Another way to quantify the ES is to compare it with
the minimal important difference (MID) [9-12]. The MID
can be defined as the smallest change in health status that
causes a significant change in the patient’s symptoms, jus-
tifying the performance or modification of a treatment if
there are no significant side effects or excessive costs. It is
estimated based on a determination of the standard error
of measurement (SEM) and is estimated as 1 x SEM. The
SEM is a statistical technique that estimates the possible
magnitude of error in a measurement and is defined as be-
ing the standard error in an observed result that masks
the true result. An important property of the SEM is that
its value is independent of the sample. This property
means it yields a good estimate of individual changes in a
health-related QoL indicator.
SEM ¼ 1−rdð Þ1=2in relation to ES
SEM ¼ SDb−SDdð Þ x 1−rdð Þ1=2in relation to SRM
rd: intraclass correlation coefficient of the differences
between baseline and follow-up for each dimension.
SDb: baseline SD of each dimension.
SDd: SD of the difference between the baseline and
follow-up groups.
The ceiling effect and the floor effect were determined
for each dimension. The floor value is considered to be
the percentage of patients who have the lowest value and
the ceiling value is the percentage of patients with the
highest value. The floor or ceiling effect is present if more
than 15% of patients reach floor or ceiling values within
each dimension.
Finally, the long-term QoL predictors were evaluated.
Statistical analysis
Quantitative variables were expressed in terms of mean
and standard deviation if normally distributed, or as within
median and interquartile range if the data were clearly
skewed. Qualitative variables were expressed as frequencies
and percentages.
The statistical Student’s T test and the Mann–Whitney
U test were used to compare the dimensions of the SF-36,
according to whether or not normality assumptions
were met. A Levene test (homogeneity of variances)
Table 1 Baseline characteristics
Age (years), mean (SD) 64.4 (10.6)
Men, n (%) 77 (81.9)
Smokers, n (%) 45 (47.9)
Alcohol, n (%) 12 (12.8)
Obesity, n (%) 24 (25.5)
Hypertension, n (%) 46 (48.9)
Diabetes mellitus, n (%) 19 (20.2)
Hyperlipidemia, n (%) 40 (42.6)
Renal failure, n (%) 8 (8.5)
Ischemic heart disease, n (%) 14 (14.9)
Myocardial infarction, n (%) 10 (10.6)
CABG*, n (%) 12 (12.8)
Heart failure, n (%) 18 (19.1)
Dilated cardiomyopathy, n (%) 21 (22.3)
Tachycardiomyopathy, n (%) 17 (18.1)
Valvular heart disease, n (%) 19 (20.2)
- Aortic stenosis 4 (4.3)
- Mitral regurgitation 12 (12.8)
- Tricuspid regurgitation 3 (3.2)
Pacemaker, n (%) 7 (7.4)
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were used to assess the nature of the distribution of each
variable. A Wilcoxon rank sum test was used to compare
the values of the transformed scores between baseline and
follow-up dimensions.
The factors related to long-term QoL (PCS and MCS at
follow-up) were determined by using a multiple linear re-
gression model, using the stepAIC function (library
MASS) and the lm function (basic library). The statistical
criterion AIC was used, so the lower the value, the better
the statistical model. Using this model we identified, based
on AIC statistic values, the group which includes all pre-
dictors that best explains the dependent variables and that
reaches statistical significance, independently of the indi-
vidual statistical significance of each variable. Both librar-
ies are freely available on the CRAN-R website.
All analyses were performed using SPSS Statistics 17.0
(SPSS Inc., Chicago, IL, USA) and R (CRAN-R, version
2.14.0).
Ethical considerations
All patients gave written informed consent and this work
has the approval of the Clinical Research Ethics Committee
of Galicia.Atrial fibrillation, n (%) 41 (43.6)
COPD†, n (%) 20 (21.3)
Asthma, n (%) 5 (5.3)
Steinert, n (%) 2 (2.1)
Arthrosis, n (%) 23 (24.5)
Oral anticoagulation, n (%) 55 (58.5)
Antiarrhythmic drugs, n (%) 47 (50.0)
Betablockers, n (%) 15 (16.0)
Verapamil/diltiazem, n (%) 21 (22.3)
Digoxin, n (%) 12 (12.8)
*CABG: Coronary Artery Bypass Graft. †COPD: Chronic Obstructive Pulmonary Disease.Results
Baseline characteristics
Most of the patients were male (82%). The mean (SD)
age was 64 (11) years. A total of 44% of patients had a
history of atrial fibrillation (AF), 50% received antiar-
rhythmic drugs (AAD) and 55 (59%) received oral antic-
oagulation (OAC). The presence of diabetes mellitus
(DM) was common (20%), 10 patients (11%) had a his-
tory of myocardial infarction, 18 (19%) of heart failure
and 21% suffered from Chronic Obstructive Pulmonary
Disease (COPD). We documented a component of tachy-
cardiomyopathy in 17 (18%) patients. Table 1 summarizes
the baseline characteristics.Outcomes during follow-up
During follow-up, 16 patients died, three were lost to
follow-up and one patient developed a dementia, so was
unable to complete the SF-36 questionnaire. Therefore, 74
patients completed the SF-36 at follow-up. The mean (SD)
age was 70 (11) years and 82% were male. Hypertension
was frequent (68%), 20% suffered from DM and 38% from
osteoarthritis. The presence of heart failure and COPD
was detected in 12% of patients. During follow-up, 51% of
patients developed AF and in 38% of cases the AF was
chronic. AFl recurrence was documented in 15 (16%) pa-
tients, of whom 14 underwent a new ablation procedure
and one patient underwent electrical cardioversion.Quality of life outcomes
At baseline, mean scores for all dimensions were lower
than mean scores for the Spanish population (mean 50,
SD 10). The highest score was obtained for Bodily Pain
(Table 2). For Physical Function, PCS and Social Function,
scores were approximately six points below the Spanish
mean scores. Differences from Spanish mean scores for
the other dimensions were more important and the lowest
score was for Physical Role (almost 9 points below the
Spanish population mean score).
At follow-up, mean scores for all dimensions were
higher than those obtained at baseline, except for Bodily
Pain, but all were lower than the Spanish population mean
scores (Table 2).
With respect to the differences between baseline and
long term QoL, there was a large difference (greater than
Table 2 Differences between follow up and baseline
scores standardized and normalized for Spanish
population and adjusted by age and sex, at baseline
and at follow-up
Dimension Basal Follow-up Difference P
Physical function 44.3 (11.9) 44.4 (10.1) 0.56 (9.8) 0.870
Physical role 38.6 (11.7) 46.4 (10.9) 8.93 (13.6) <0.001
Bodily pain 48.3 (10.7) 44.8 (9.7) −3.77 (10.6) 0.003
General health 42.8 (9.4) 43.6 (9.9) 1.23 (8.7) 0.226
Vitality 41.9 (10.9) 44.4 (12.0) 2.35 (10.6) 0.038
Social function 43.5 (15.2) 44.2 (13.4) 0.17 (13.6) 0.717
Emotional role 40.4 (15.9) 43.0 (16.0) 2.69 (19.9) 0.142
Mental health 42.0 (11.3) 46.1 (11.4) 4.33 (11.2) 0.001
PCS* 44.6 (10.3) 45.1 (10.1) 0.48 (11.0) 0.596
MCS† 41.2 (14.8) 44.5 (15.0) 3.29 (15.4) 0.057
*PCS: Physical Component Summary. †MCS: Mental Component Summary.
Table 3 Minimal important differences in relation to
effect size and standardized response mean
Dimension Mean (SD) ES* SRM† MID (ES)‡ MID (SRM)§
Physical function 0.2 (10.4) 0.08 0.02 0.50 0.58
Physical role 8.5 (13.4) 0.67 0.63 0.65 0.59
Bodily pain −3.7 (10.1) 0.32 0.37 0.60 0.63
General health 1.3 (8.8) 0.08 0.15 0.51 0.54
Vitality 2.3 (10.3) 0.23 0.22 0.51 0.53
Social function 0.5 (12.3) 0.05 0.04 0.47 0.58
Emotional role 2.8 (16.3) 0.03 0.17 0.58 0.57
Mental health 4.2 (10.8) 0.35 0.39 0.54 0.56
PCSǁ 0.7 (11.0) 0.05 0.06 0.63 0.60
MCS# 3.3 (14.8) 0.22 0.22 0.56 0.57
Physical Role was the only dimension that achieved the threshold established
for MID (bold numbers), see text for explanation. *ES: Effect Size. †SRM:
Standardized Response Mean. ‡MID (ES): Minimal Important Differences in
relation to ES. §MID (SRM): Minimal Important Differences in relation to SRM.
ǁPCS: Physical Component Summary. #MCS: Mental Component Summary.
Table 4 Statistical model for the physical component
summary
Variables Estimated coefficient Se** T value P
Constant 32.14 4.99 6.4 < 0.0001
DM* −4.29 2.73 −1.6 0.1202
OAC† −3.91 2.26 −1.7 0.0881
AF‡ −3.18 2.25 −1.4 0.1618
Reflutter§ −5.91 2.34 −2.5 0.0139
Basal PCSǁ 0.32 0.10 3.1 0.0027
AIC# = 333.43 adjusted R2 = 0.244 p = 0.00019
*DM: previous diabetes mellitus. †OAC: previous oral anticoagulation. ‡AF:
previous atrialfibrillation.§Reflutter: atrial fultter recurrence. ǁBasal PCS: basal
Physical Component Summary, adjusted by age and sex. #AIC: model’s statistic.
**SE: standard error.
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(between four and six) for Mental Health (p = 0.001)
and a very small difference (less than four) for Vitality
(p <0.001) and Bodily Pain (p = 0.003); the last of these
had the lowest score at follow-up. Table 2 summarizes the
scores at baseline and at follow-up, with their differences.
The smallest change in health status perceived by the
patient was evaluated using the differences between the
QoL at baseline and at follow-up in relation to ES and
the SRM. The values were similar for both indicators.
Physical Role was the only dimension that achieved the
threshold established for MID because the change (0.67
for ES and 0.63 for SRM) exceeded the minimum re-
quired to be clinically perceived by the patient on the
Physical Role (0.65 for ES and 0.59 for SRM). Table 3
summarizes the values.
At baseline and at follow-up a ceiling effect was deter-
mined for Physical Role, Bodily Pain, Social Function and
Emotional Role, and a floor effect was determined for
Physical Role and Emotional Role, so more questions
would probably be required to evaluate these dimensions
more effectively in order to assess changes with regard to
the baseline scores after typical AFl ablation. Both Role di-
mensions often have a ceiling or floor effect in the pub-
lished literature [13,14]. The General Health, Vitality and
Mental Health dimensions showed neither a ceiling nor a
floor effect, neither at baseline, nor at follow-up.
Factors related to long-term QoL were evaluated using
two multiple linear regression models in which the
dependent variables were the PCS and MCS, and the inde-
pendent variables were the baseline PCS and MCS, the
history of DM, AF, OAC, heart failure, COPD, osteoarth-
ritis, the occurrence of AF during follow-up and AFl re-
currence. The set of variables that best explained the PCSwere the baseline PCS, AFl recurrence, previous AF, OAC
and DM (p <0.001) (Table 4). For the MCS, the final
model included DM and the baseline MCS (p = 0.02)
(Table 5).
Discussion
The main finding of our study was the improvement of
QoL over a long-term period in a group of patients with
typical AFl undergoing CTI ablation. This is, to the best of
our knowledge, the first study to assess QoL in this popu-
lation over a long-term period such as this (more than five
years) and that used MID to assess QoL changes perceived
by the patient. The SF-36 questionnaire is an extensively
validated generic QoL measure and has been used in the
study of numerous health conditions, including AFl [5].
Unlike other studies, we also used the MID to evaluate dif-
ferences in QoL. It is important to determine MID be-
cause it enables an assessment of whether typical AFl
Table 5 Statistical model for the mental component
summary
Variables Estimated coefficient Se§ T value P
Constant 38.83 3.21 12.1 < 0.0001
DM* −5.86 3.02 −1.9 0.0464
Basal MCS† 0.18 0.07 2.4 0.0196
AIC‡ = 386.61 adjusted R2 = 0.077 p = 0.02175
*DM: previous diabetes mellitus. †Basal MCS basal: basal Mental Component
Summary, adjusted by age and sex. ‡AIC: model’s statistic. §SE: standard error.
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tion as providing enough benefit to make this treatment
acceptable, in the absence of excessive cost or severe side
effects, regardless of the differences determined by statis-
tical analysis, and thereby an assessment of treatment
efficacy. In addition, all scores were standardized and
normalized for the Spanish population, adjusted for age
and sex, which allowed our results to be compared with
the Spanish general population.
Patients had a low score for all SF-36 questionnaire di-
mensions at baseline. After a long-term follow-up, all di-
mensions were higher and Physical Role, Vitality and
Mental Health significantly improved; however, we only
observed a significant MID for Physical Role. This is very
important because it indicated that improvements in QoL
after CTI ablation are not in fact perceived by the patient
in long-term follow-up, except for Physical Role, suggest-
ing that this dimension is particularly affected in AFl and
CTI ablation provides an improvement after several years,
although, because of its ceiling effect, we cannot know
exactly the magnitude of improvement on QoL.
The baseline dimensions were very low and, probably,
the existence of comorbidity factors such as DM, heart
failure and osteoarthritis partly contributed to these find-
ings. These chronic afflictions have an impact on QoL
and, in fact, chronic diseases such as arthritis or osteoarth-
ritis may condition a nine-point difference for the Physical
Function dimension, and others, such as DM or heart fail-
ure, can explain a difference of up to 13 points [15].
Previous studies that assessed the basal QoL showed
similar results [16,17]. The baseline characteristics of our
study population are comparable to other studies of AFl
ablation [5,16-18]; however, in our population there was a
greater proportion of DM (20%, compared to 7–15% de-
scribed elsewhere). Furthermore, these similar findings
were published in relation to other arrhythmias, such as
AF [17,19,20], which is usually better tolerated than AFl.
Thus, Lönnerholm, et al. [19] reported a reduced basal
QoL in patients with AF, both for the Physical and Mental
Functions, even when values were lower than those pub-
lished in the Medical Outcome Study [15], which included
patients with symptomatic chronic left ventricular dys-
function (dyspnea, edemas,…), hypertensive patients with
very severe symptoms and severe heart failure and/orstroke, patients with previous myocardial infarction and
heart failure or patients with severe angina and diabetes
with multiorgan involvement.
The basal dimension with the highest score was Bodily
Pain, which seems not to be very important role for pa-
tients with AFl; indeed, the most common symptoms as-
sociated with AFl are palpitations, shortness of breath or
occasionally heart failure and, rarely, chest pain [4].
At follow-up, scores were higher than baseline scores
for all dimensions of health, except for Bodily Pain, the
worst scores for which could be explained by an increase
in age-related noncardiac comorbidities such as, for ex-
ample, osteoarthritis. There was a significant difference
between follow-up and baseline scores for Physical Role,
Vitality and Mental Health. The improvement for Mental
Health and Vitality is important because these dimensions
showed neither a ceiling nor a floor effect, which means
that the SF-36 questionnaire can reliably perceive positive
or negative changes for these dimensions. Moreover, Vital-
ity is an important dimension because it represents the
physical and mental aspects of health. However, all scores
were low in relation to the Spanish general population. It
is possible that associated comorbidities could explain this
finding.
Several studies in the literature [16,17,21-23] have de-
scribed a significant and important improvement in QoL
after AFl ablation in short- to medium-term follow-up.
In our study, we found a smaller improvement, probably
because of the longer follow-up period. Our study ex-
tends the follow up and a longer follow-up facilitates the
onset of age-related comorbidities and the progression
of baseline chronic diseases, such as diabetes mellitus;
both phenomena are associated with an impairment on
QoL. This fact can contribute to the lower QoL, regard-
less of the ablation procedure. Even thus, there was an
improvement on long-term QoL after CTI ablation with
respect to baseline QoL. So, these findings support the
AFl conditions an important deterioration on QoL and
the ablation provides an improvement on QoL not only
in the short- to medium-term, as previously described,
but also in the longer term.
The main determinants of long-term QoL that we
found were the baseline QoL, AFl recurrence, the previ-
ous DM, OAC and AF. AFl recurrence often presents
with high ventricular rates, which makes it a very symp-
tomatic arrhythmia; it is more difficult to achieve an ap-
propriate rate control using antiarrhythmic drugs. That is
why this arrhythmia has an important impact on QoL. In
our study, all patients with typical AFl recurrence under-
went a reablation procedure, except for one individual
who underwent electrical cardioversion with no more AFl
clinical episodes. DM is a chronic progressive disease asso-
ciated with multiple complications, and so, by the time of
follow-up, the disease has progressed and complications
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ation in QoL, both for physical and mental health, was
more pronounced in these patients compared to those
who do not suffer from DM. It is well known that the
presence of AF is associated with impaired QoL, which
significantly improves when a good heart rate control or
sinus rhythm is achieved. OAC is very likely to be a risk
indicator in patients who receive it, indicating that it is
used in patients with more comorbidities and therefore at
high risk of complications and impaired QoL. In addition,
the numerous controls used to optimize the dose of anti-
coagulant therapy in patients with restricted mobility and
who live far from health centers, such as it occurs in our
study population, could contribute to a loss of QoL.
So, patients that have undergone AFl ablation consti-
tuted a population presenting comorbidities that probably
influenced the deterioration of QoL at baseline and at
long-term follow-up. Nevertheless, ablation provided a
significant improvement, chiefly for Physical Role, Vitality
and Mental Health, and patients were able to perceive this
improvement for Physical Role.
Finally, the questionnaire completion rate was excel-
lent; all patients answered the questionnaire at baseline
(prior to ablation procedure) and at follow-up. There-
fore, there were neither blank questionnaires nor incom-
plete items, unlike other studies [13,24,25] in which the
questionnaire was retrospectively completed, making it
more difficult to complete and to evaluate the health sta-
tus before and after a particular treatment.
Limitations
This study was developed in a single hospital in Spain, so
the interpretation of the results should be made with cau-
tion. More studies are needed to replicate these findings.
The SF-36 is a generic questionnaire that evaluates most
of the health-related areas relevant to multiple diseases and
their treatment but, as a generic questionnaire, it is not de-
signed to assess specifically QoL related to the treatment
of arrhythmias. Furthermore, there are some important
health aspects that are not covered in this questionnaire,
such as sleep disorders, eating disorders, familial function,
sexual function or cognitive function. In addition, both the
ceiling and floor effect were observed for some dimensions,
probably indicating that the SF-36 is not quite sensitive
and specific enough to detect changes in these dimensions
after the ablation procedure.
Conclusion
CTI ablation of typical AFl provided a significant im-
provement in Physical Role, Mental Health and Vitality
dimensions in a long-term follow-up, but MID was only
observed for Physical Role. The main determinants of
long-term QoL in these patients were baseline QoL, re-
currence of AFl and a history of DM, AF and OAC.Abbreviations
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